Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Peripheral arterial disease (PAD) severely impairs patient prognosis and quality of life (QoL). Although lipoprotein apheresis (LA) has been applied to patients with PAD and elevated serum atherogenic lipoproteins in Japan, studies have suggested potential mechanisms of LA beyond lipoprotein removal. We hypothesized that LA can be effective for treating PAD even in patients without concurrent severe dyslipidemia through pleiotropic anti-atherosclerotic effects. Therefore, we evaluated the efficacy of LA in patients with PAD and controlled serum lipoproteins, focusing on QoL. Additionally, we evaluated changes in serum profiles before and after LA using a comprehensive analysis to explore the underlying mechanism.
We conducted a single-arm prospective study. A total of 30 patients with refractory PAD who had controlled serum lipoproteins underwent sequential LA sessions using dextran sulfate adsorption columns, aiming to complete 10 sessions. The ankle-brachial pressure index (ABI) and vascular QoL (VascuQoL) score were the primary outcomes. Secondary outcomes included reactive hyperemia index (RHI) and biological antioxidant potential (BAP) as an endothelial function test and serum antioxidative-capacity evaluation, respectively.Additionally, proteomic analysis was performed on serum samples from the participants with Fontaine stage IV PAD (with lower limb ulcers) at baseline and 1 month after completing LA to measure serum protein changes.
ABI significantly increased after LA sessions (baseline 0.60±0.09 vs 1 month after treatment 0.65±0.13, p= 0.023). Total VascuQoL score (3.7±1.1 vs 4.6±1.1, p<0.001) and RHI (1.70±0.74 vs 2.34±1.76, p=0.023) significantly improved at 1 month after the LA sessions. The improvements in ABI and QoL were sustained 3 months after LA. BAP tended to increase at 1 month after the LA sessions, and the change reached statistical significance at 3 months after the treatment.Among 10 patients with Fontaine stage IV PAD, the lower limb ulcer scores significantly improved from a pre-treatment median of 9 (interquartile range 6-15.75) to 0 (0-15.5) one-month after treatment (p=0.030), with epithelialization observed in 6 patients. Proteomic analysis of serum samples collected before and after treatment identified 20 proteins showing significant and marked changes (>2-fold or <0.5-fold of baseline) in expression levels at 1 month after treatment. Decreased proteins included those exhibiting pro-apoptotic and anti-angiogenic effects.
ABI and QoL improved after a series of LA sessions in patients with treatment-resistant PAD without severe dyslipidemia. Increased antioxidative capacity and ameliorated endothelial function were observed after LA. Proteomic analysis of the sera obtained after LA showed marked reductions in proteins promoting apoptosis and inhibiting angiogenesis.
